NewCellX

NewCellX is an innovative biotechnology company specializing in the development of next-generation cell therapies for oncology and immunology. Utilizing its proprietary NCX™ platform, the company focuses on non-viral cell engineering to produce high-potency, "off-the-shelf" CAR-T and CAR-NK cell therapies. This approach is designed to overcome the logistical and cost barriers associated with traditional viral-based manufacturing while enhancing therapeutic efficacy against solid tumors. NewCellX is currently progressing its lead programs through pre-clinical validation, targeting both refractory cancers and severe autoimmune conditions. The company's technology aims to improve the scalability and safety profile of cellular medicines for broader patient access.